Summary
Introduction
Several lines of evidence suggest that an impairment of the ability to augment the synthesis of endogenous prostaglandins underlies the renal dysfunction in a number of clinical disorders. Thus, the administration of prostaglandin synthetase inhibitors to patients with decompensated cirrhosis, congestive heart failure, and nephrotic syndrome sometimes results in significant decrements in renal blood flow, glomerular filtration rate, and sodium excretion [1-31. Implicit in these reports is the possibility that the augmentation of endogenous prostaglandins might improve renal function.
Theoretical considerations suggest that the provision of essential fatty acids would augment endogenous prostaglandins. Under normal circumstances the body converts linoleic acid to arachidonic acid. Since arachidonic acid is the precursor of prostaglandins of the two series including E, and I,, it appeared reasonable to provide this precursor to assess the augmentation of endogenous prostaglandins. In the present study, we administered Liposyn, a fat emulsion derived from safflower oil, to a group of normal subjects.
Methods
A total of ten studies (five control and five fatty acid infusion) were carried out in six normal male subjects (four of the subjects underwent both studies). In the four subjects who underwent both studies, the order of studies was varied so that two underwent a control study followed by fatty acid infusion, whereas the remaining two underwent a fatty acid infusion first. The subjects ranged in age from 22 to 35 years [mean 29 k 2 (sE)]. The mean body weight of the group was 71.4 2-7 kg (range 65-80 kg). All subjects were normotensive at the time of study, and all had negative histories for hypertension, cardiovascular disease and diabetes. Clinically apparent renal disease was excluded by documenting a normal urine sediment, creatinine clearance, and negative urine cultures. The subjects did not ingest diuretics, nonsteroidal anti-inflammatory drugs, or other agents that might have influenced prostaglandin synthesis. An interval of at least 5-6 days separated the control and fatty acid infusion studies in the four subjects who underwent both studies. The subjects ingested unrestricted diets. Mean urinary sodium excretion on the day before study was 153 f 27 mmollday.
The experimental protocols on the two study days were similar and were carried out as follows. After 1 1 h of overnight fluid restriction, the subject voided at 08.00 hours and then sat quietly for 1 h. At 08.15 hours, an oral water load of 300 ml was administered. At 09.00 hours, after voiding and completely emptying his bladder, the subject once again assumed the seated position for the remaining 8 h. Before and after the study, blood samples were obtained for sodium, potassium, and creatinine determinations.
During the study, each subject stood briefly to void spontaneously at 2 h intervals. To maintain an adequate urine flow, 200 ml of water was administered orally every 2 h during the study. Sodium, potassium and creatinine were measured in samples of the 2 h urine collections, and samples of each urine specimen were frozen promptly for determination of immunoassayable PGE and immunoassayable 6-0x0-PGF,,.
During the fatty acid infusion study, each subject received an infusion of long-chain essential fatty acids as a 10% emulsion of safflower oil (Liposyn) in a dose of 1.5 g/kg body weight. The fatty acid components of safflower oil are: linoleic, 77%; oleic, 13%; palmitic, 7%; stearic, 2.5%. The fat emulsion was administered into a peripheral vein. At 09.00 hours, an infusion of the fat emulsion was started at a rate of 0-1 ml/min. If after 15 min no adverse effects were observed, the rate was increased to 100-110 ml/h. Vital signs, including pulse rate and blood pressure, were noted prior to and at the termination of study. No special side effects were noted aside from a feeling of discomfort at the infusion site in two instances when the infusion transiently exceeded 110 ml/h. Urine PGE was assayed by a radioreceptor Urinary 6-oxo-PGFIa was determined by radioimmunoassay as follows. A 1 or 2 ml sample of urine was labelled with approx. 1000 c.p.m. of ~-oxo-[~H]PGF,,. The pH of the samples was adjusted to 3.0 with 0-1 moll1 HCl. The samples were twice extracted with 20 ml of chloroform. The chloroform was then flashevaporated and the 6-oxo-PGF1, extract was resolubilized in a phosphate/saline buffer, pH 3.0. This phosphate/saline buffer, containing 6-oxo-PGFIu, was passed through a Sep-Pak cartridge (Waters Associates, Milford, MA, U.S.A.). This procedure allows the 6-oxo-PGF1, to bind to the Sep-Pak cartridge. It was subsequently eluted from this cartridge with 3 ml of methanol, blown to dryness under nitrogen, and then stored in ethanol prior to high pressure liquid chromatography. Recovery of the radioactive 6-oxo-PGF1, with this procedure averaged 72 f 7%. High pressure liquid chromatography with a reverse phase column and acetonitrile/ water (7 : 18, v/v) as the solvent system was then performed to separate the 6-oxo-PGF1, from other prostaglandin products. The appropriate fractions eluted from the high pressure liquid chromatography column were entered into a traditional radioimmunoassay along with standard chemical 6-oxo-PGFlu (obtained from the Upjohn Company) and trace amounts of tritiated ~-OXO-[~H]PGF,, (New England Nuclear). Antibody directed towards 6-0x0-PGF,, was used in a final dilution of 1 :20 000. All tubes were incubated in a covered rack at 37OC in a shaking water bath for 1 h and subsequently placed in an ice bath. Separation of bound from free 6-oxo-PGF1, was effected with dextran-coated charcoal. All samples were run in duplicate and at either two or three dilutions. The antibody is quite specific for 6-oxo-PGF1,, although when PGI, was added to the assay tubes it reacted as well as 6-oxo-PGF1,, perhaps due to conversion to 6-oxo-PGF,, in the assay tube itself. Because of the degree of sensitivity of the standard curve, calculations of samples were corrected for the chemical amount of 6-0x0-PGF,, included in the radioactive trace. In eight different samples run on four different days, recovery of added known amounts of 6-0x0-PGF,, averaged 11 1 f 15%.
To evaluate whether Liposyn itself might interfere with the assay procedures, we performed extractions on three samples of urine to which Liposyn was added. Following the addition of 0.1 ml of Liposyn emulsion to either 1 or 2 ml samples of urine, these samples were carried through the extraction procedure and assayed by radioreceptor assay (PGE) or radioimmunoassay (6-oxo-PGF1,), and the results were compared with the same samples run without additional Liposyn. There was no increase in the amounts of either immunoassayable PGE or 6-0x0-PGF , , in these urine samples as compared with the sample of urine without addition of Liposyn. Thus, there are apparently no substances in Liposyn that react in the extraction or assay procedures as either immunoassayable PGE or immunoassayable 6-oxo-PGF1,.
Analytical methods for sodium, potassium, and creatinine have been reported previously 141. In the presentation of the data, mean values are followed by the standard error of the mean as an index of dispersion. Data were evaluated statistically by paired or unpaired t-tests or by twofactor analyses of variance for experiments having repeated measurements on the same subject [51. If a significant effect was detected, the Newman-Keuls test was used to determine which treatment means were significantly different [51. Differences with P < 0.05 were considered significant.
Permission for the study was obtained from each subject after a detailed description of the procedure and potential complications. 
Results

Fluid and electrolyte excretion
The effects of a control study and the infusion of fatty acids on urinary fluid and electrolyte excretion are shown in Table 1 . Urinary flow rate ( V ) tended to increase during the control study, although mean V exceeded the pre-study value only during hour 3. The infusion of fatty acids tended to result in increases in V during all four periods ( P < 0.05 compared with preinfusion), but the mean values were not significantly different from the corresponding control values.
The rate of sodium excretion (U,,V) was relatively constant throughout the control study, ranging from 120 to 134 pmol/min. Mean U,,V during the infusion of fatty acids was unaltered Results are means k SE of five subjects: difference from control: *P < 0.05.
Time periods
Group
Re-study The rate of potassium excretion (UKV) was relatively constant throughout the control study. The infusion of fatty acids was associated with a decrement in UKV during periods 3 and 4 compared with the corresponding control study.
Creatinine clearance (C,J was unaltered throughout the control study. Fatty acid infusion did not alter C,, as compared with either the corresponding control study or the pre-infusion hour.
Urinary immunoassayable prostaglandin excretion
Urinary immunoassayable 6-oxo-PGF1,. The effects of control and fatty acid infusion on urinary immunoassayable 6-oxo-PGF1, excretion are shown in Fig. 1 . Immunoassayable 6-oxo-PGF1, excretion was relatively constant during the control study, ranging from 1.3 to 1.9 -c , CUI
.- 
-
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Fatly acid inlusion I I c nglmin. Fatty acid infusion was associated with a profound increase in immunoassayable 6-0x0-PGF,, excretion, which increased from a preinfusion mean of 1.8 f 0.2 to peaks of 5.6 f 0.9 and 5 . 5 f 1.1 nglmin during periods 2 and 3 of infusion (P < 0.01 and <0.05, respectively).
Furthermore, a comparison of control and fatty acid infusion disclosed that the latter values exceeded control during all four periods of study.
The cumulative quantities of immunoassayable 6-oxo-PGF1, excreted over the 8 h period of control and fatty acid infusion were also compared. Mean immunoassayable 6-oxo-PGF,, excretion during the infusion of fatty acids was 2504 f 187 ng/8 h, markedly greater than the 790 f 160 ngI8 h excreted during the control period ( P < 0.001).
Urinary PGE. The effects of control and fatty acid infusion on urinary immunoassayable PGE excretion are shown in Fig. 2 . During the 9 h of control, mean U, , , V was relatively constant, ranging from 1.3 to 2.9 nglmin. In contrast, fatty acid infusion resulted in an increase in immunoassayable PGE excretion during periods 2, 3 and 4 of infusion as compared with the pre-infusion hour (P < 0.05). A comparison of control and Linoleic acid, the most common dietary essential fatty acid, is readily converted to linolenic and then to arachidonic acids t71. Subsequent conversion of arachidonic acid to prostaglandins also occurs in a number of mammalian tissues. The potential for administering linoleic acid as a means of augmenting prostaglandin production has been suggested [8, 91. Although the observed effects in the latter studies were attributed to the actions of prostaglandins, prostaglandin levels were not measured. To our knowledge, however, the intravenous administration of linoleic acid has apparently not previously been evaluated as a means of augmenting endogenous prostaglandin production in man.
The current study demonstrates that the infusion of a fatty acid emulsion which is rich in linoleic acid resulted in a marked increase in urinary excretion of immunoassayable 6-0x0-PGF,,. In contrast, when identical studies were conducted during the same time of day but without fatty acid infusion (control studies), there was no significant increase in urinary immunoassayable 6-oxo-PGFI, excretion. Simultaneously, the infusion of fatty acids resulted in a modest increase in immunoassayable PGE excretion.
Although the augmentation in PGE excretion was not as striking as that observed for 6-oxo-PGF1,, immunoassayable PGE excretion during fatty acid infusion did exceed the pre-infusion levels during three of the periods of infusion. Furthermore, cumulative immunoassayable PGE excretion during the 8 h of infusion exceeded the values documented during the corresponding control periods.
The possibility must be considered that effects related to the experimental design, other than the infusion of fatty acids, might explain the alterations in prostaglandin excretion. Although it is possible (albeit unlikely) that Liposyn itself might affect the assay procedures with a factitious increase in the levels of immunoassayable PGE and 6-oxo-PGF,,, we demonstrated that the addition of Liposyn to urine did not alter the results of the assay. Among the factors that appear to affect the rate of urinary immunoassayable PGE excretion (and perhaps 6-0x0-PGF,, excretion) is urinary flow rate, particularly higher urine flow rates [lo] . Despite such observations, it is unlikely that flow rate could have accounted for the striking differences observed during control and fatty acid infusion. Although urine flow tended to increase during the fatty acid infusion study, the values did not differ statistically from the corresponding values during the control study.
If these results, in fact, do indicate an increase in endogenous prostaglandin production following linoleic acid administration, it is of interest to consider which organs or cell type might be responsible. Although most mammalian cells are assumed to have the ability to convert linoleic acid to arachidonic acid, a recent study by Spector et al. [ 1 1 I suggests that at least umbilical vein endothelial cells are lacking in this ability. Whether this generalization holds for endothelial cells of a more mature nature or endothelial cells from other organs has not been addressed at present.
It is of interest to consider the implications of an increase in 6-oxo-PGF1, excretion. Since 6-oxo-PGF1, is recognized as one of the major non-enzymic breakdown products of PGI,, the demonstration of an increase in immunoassayable 6-oxo-PGF1, suggests that the infusion of fatty acid augmented PGI, production. Although qualitative inferences are possible, it is not possible to assess quantitatively the magnitude of PGI, augmentation. The exact fraction of PGI, which is converted to 6-oxo-PGF1, in mammals has been estimated to range from approx. 9% in the rat [12] to 13% in the monkey [131. Thus, although 6-oxo-PGF1, is a major product of PGI, catabolism, a number of other products exist as well.
The disparity between the marked increase in urinary immunoassayable 6-0x0-PGF l a excretion and the relatively modest increase in urinary immunoassayable PGE excretion merits com-ment. These observations are consistent with the suggestion that fatty acid administration augments primarily PGI, production and that such augmentation derives from systemic rather than renal PGI, production. Since thromboxane B, was not measured in this study, the possible augmentation of thromboxane A, production by Liposyn cannot be ascertained.
The absence of an increase in urine flow rate, sodium excretion, or creatinine clearance despite augmentation of PGI, production (and to a lesser extent PGE production) merits discussion. It has been previously demonstrated that both PGI, and PGE,, when administered into the renal artery, lead to increases in sodium excretion [14, 151. Furthermore, the intrarenal administration of PGE, markedly increases urine flow rate [ 151. In the current study, the lack of a significant change in either urine flow rate or sodium excretion militates against major effects for either of these prostaglandins at the level of the kidney in the present protocol.
An alternative explanation is possible. As we have noted elsewhere [3], accumulating evidence suggests that the extent to which renal prostaglandins modulate renal function is determined in great part by the volume status of the subject. Thus, the administration of prostaglandin synthetase inhibitors to normal subjects blunted sodium excretion in the sodium-depleted state, but not in the sodium-replete state, despite comparable suppression of basal urinary immunoassayable PGE [41. According to this formulation, renal prostaglandins are critical modulators of renal function only during conditions or disease states characterized by volume contraction. If this formulation is correct, it would be anticipated that an augmentation of renal prostaglandins might affect renal function only during the sodium-depleted state, and not in the sodium-replete state such as that which obtained in the present study.
A third explanation is possible. Although we did not estimate thromboxane A, activity, it is possible that the increase in PGI, was attended by a concomitant increase in thromboxane A,. If such events occurred, the haemodynamic effects of PGI, might be counteracted, without a resultant change in renal haemodynamics. Additional studies will be necessary to assess this possibility.
If in fact, Liposyn administration does augment endogenous PGI, production, its potential clinical utility might be considerable. The possible role of prostaglandins in decreasing both systemic and pulmonary as well as renal vascular resist-
ance has yet to be explored in clinical disease states for lack of a clinical means of increasing their endogenous production. It would seem appropriate to determine blood levels of 6-0x0-PGF during Liposyn administration to ascertain whether, in fact, these levels are increased and perhaps to monitor systemic haemodynamic consequences including cardiac output, peripheral and pulmonary vascular resistance.
In summary, the present studies demonstrate that Liposyn infusion augments the rate of excretion of immunoassayable 6-oxo-PGF1, and PGE, although levels of the former increased to a greater extent. This might be due to differences in the rate of metabolism of these two prostaglandins. These findings are consistent with the formulation that the linoleic acid found in Liposyn material is, in part, converted to arachidonic acid and subsequently to prostaglandins within the normal human subject. To our knowledge, this study constitutes the first demonstration that provision of linoleic acid can increase prostaglandin production in man. This finding may prove to have clinical utility. For example, it is conceivable that augmentation of prostaglandins might ameliorate the renal dysfunction associated with disease states such as cirrhosis of the liver in which the compensatory ability to augment prostaglandin synthesis is impaired.
